FGF2 and Miyoshi myopathy: Likewise, rHuEPO decreases the activation marker (αSMA and FAP) expression in MGUS and MM; furthermore, proinflammatory and proangiogenic cytokines, such as IL-6 and IL-8, VEGF-A, FGF-2, and HGF in MM fibroblasts, significantly diminished.